Original Article

You have full text access to this OnlineOpen article

The cost of hepatitis A infections in American adolescents and adults in 1997

  1. Jeremy J. Berge1,
  2. David P. Drennan1,
  3. R. Jake Jacobs M.P.A2,*,
  4. Alan Jakins3,
  5. Allen S. Meyerhoff2,
  6. Wayne Stubblefield4,
  7. Melvyn Weinberg5

Article first published online: 30 DEC 2003

DOI: 10.1002/hep.510310229

Issue

Hepatology

Hepatology

Volume 31, Issue 2, pages 469–473, February 2000

Additional Information

How to Cite

Berge, J. J., Drennan, D. P., Jacobs, R. J., Jakins, A., Meyerhoff, A. S., Stubblefield, W. and Weinberg, M. (2000), The cost of hepatitis A infections in American adolescents and adults in 1997. Hepatology, 31: 469–473. doi: 10.1002/hep.510310229

Author Information

  1. 1

    Private Practice, San Francisco, CA

  2. 2

    Capitol Outcomes Research, Inc., Alexandria, VA

  3. 3

    Private Practice, Roswell, NM

  4. 4

    Private Practice, Oklahoma City, OK

  5. 5

    Campus Health Service, University of Arizona, Tucson, AZ

*Capitol Outcomes Research, Inc., 6188 Old Franconia Road, Alexandria, VA 22310. fax: (703) 922-1853

Publication History

  1. Issue published online: 30 DEC 2003
  2. Article first published online: 30 DEC 2003
  3. Manuscript Accepted: 25 OCT 1999
  4. Manuscript Received: 11 MAY 1999

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (83K)

References

  • 1
    Hadler SC. Global impact of hepatitis A virus infection: changing patterns. In: FBHollinger, SMLemon, HSMargolis eds. Viral Hepatitis and Liver Disease. Baltimore, MD: Williams & Wilkins. 1991;14–19.
  • 2
    Hepatitis Surveillance Report Number 56. Atlanta, GA: Centers for Disease Control and Prevention. 1996.
  • 3
    Shapiro CN, Coleman PJ, McQuillan GM, Alter MJ, Margolis HS. Epidemiology of hepatitis A: seroepidemiology and risk groups in the USA. Vaccine 1992; 10(Suppl 1):59S–62S.
  • 4
    Tormans G, Van Damme P, Van Doorslaer E. Cost effectiveness analysis of hepatitis A prevention in travellers. Vaccine 1992; 10(Suppl 1):88S–92S.
  • 5
    Van Doorslaer E, Tormans G, Van Damme P. Cost effectiveness analysis of vaccination against hepatitis A in travellers. J Med Virol 1994; 44:463–469.MEDLINE
    Direct Link:
  • 6
    Shapiro C, Arcani C, Mast E, Bell B, Coleman P, Haddix A, Margolis H. An economic analysis of the uses of hepatitis A vaccine to control community wide epidemics. Presented at the IX Triennial International Symposium on Viral Hepatitis and Liver Disease. Rome, Italy, April 21–25, 1996.
  • 7
    Smith S, Weber S, Wiblin T, Nettleman M. Cost-effectiveness of hepatitis A vaccination in healthcare workers. Infect Control Hosp Epidemiol 1997; 18:688–691.MEDLINE
  • 8
    Das A. An economic analysis of different strategies of immunization against hepatitis A virus in developed countries. Hepatology 1999; 29:548–552.MEDLINE
    Direct Link:
  • 9
    Jacobs RJ, Meyerhoff AS. Vaccination of sexually active homosexual men against hepatitis A: analysis of costs and benefits. Journal of the Gay and Lesbian Medical Association 1999; 3:51–58.
  • 10
    Alter MJ, Mares A, Hadler SC, Maynard JE. The effect of underreporting on the apparent incidence and epidemiology of acute viral hepatitis. Am J Epidemiol 1987; 125:133–139.MEDLINE
  • 11
    Jones J, Hunter D. Consensus methods for medical and health services research. BMJ 1995; 311:376–380.MEDLINE
  • 12
    Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 1996; 45(RR-15):4–5.
  • 13
    McNeil M, Hoy JK, Richards MJ, Lehmann NI, Dimitrikakis M, Gust ID, Lucas CR. Aetiology of fatal viral hepatitis in Melbourne: a retrospective study. Med J Aust 1984; 141:637–640.MEDLINE
  • 14
    Papaevangelou G, Tassopoulos N, Roumeliotou-Karayannis A, Richardson C. Etiology of fulminant viral hepatitis in Greece. Hepatology 1984; 4:369–372.MEDLINE
    Direct Link:
  • 15
    Vento S, Garofano T, Renzini C, Cianelli F, Casali F, Ghironzi G, Ferraro T, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338:286–290.MEDLINE
  • 16
    O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97:439–445.MEDLINE
  • 17
    Margolis HS, Alter MJ. Will hepatitis A become a vaccine-preventable disease? Ann Intern Med 1995; 122:464–465.MEDLINE
  • 18
    Tilzey AJ, Banatvala JE. Hepatitis A: changing prevalence and possible vaccines. BMJ 1991; 302:1552–1553.MEDLINE
  • 19
    Hospital Statistics. The AHA Profile of United States Hospitals. Chicago, IL: American Hospital Association. 1996.
  • 20
    Fee and Coding Standard. National Pricing Guide for Setting Fees — 1997. Salt Lake City, UT: Medicode, Inc. 1997.
  • 21
    1997 Drug Topics Redbook. Montvale, NJ: Medical Economics Co. 1997.
  • 22
    Hauboldt RH. Cost implications of human organ transplantation, an update: 1993. Seattle, WA: Milliman & Robertson, Inc. 1993.
  • 23
    Haddix AC, Shaffer PA. Cost-effectiveness analysis. In: ACHaddix, SMTeutsch, PAShaffer, DODuñet eds. Prevention Effectiveness — A Guide to Decision Analysis and Economic Evaluation. New York, NY: Oxford University Press. 1996;116–118.
  • 24
    Jacobs P, Fassbender K. The measurement of indirect costs in the health economics literature. Int J Technol Assess Health Care 1998; 14:799–808.MEDLINE
  • 25
    Douglas J, Kenney G, Miller T. Which estimates of household production are best? J Forensic Economics 1990; 4:25–45.
  • 26
    Employment Cost Index — March, 1997. Washington, DC: Bureau of Labor Statistics. April 29, 1997.
  • 27
    Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Rossell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996; 276:1253–1258.MEDLINE
  • 28
    Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1999; 48(RR-12):14–15.
  • 29
    Dalton CB, Haddix A, Hoffman RE, Mast EE. The cost of food-borne outbreak of hepatitis A in Denver, CO. Arch Intern Med 1996; 156:1013–1016.MEDLINE
  • 30
    Fox-Ray N, Thamer M, Gardner E, Chan JK. Economic consequences of diabetes mellitus in the U.S. in 1997. Alexandria, VA: American Diabetes Association. 1998.
  • 31
    Rice DP, Miller LS. Health economics and cost implications of anxiety and other mental disorders in the United States. Br J Psychiatry 1998; 173(Suppl 34):4S–9S.
  • 32
    Phillips S, Fox N, Jacobs J, Wright WE. The direct medical costs of osteoporosis for American women age 45 and older, 1986. Bone 1988; 9:271–279.MEDLINE
  • 33
    Innis BL, Snitbhan R, Kunasol P, Laorakpongse T, Poopatanakool W, Kozik CA, Suntayakorn S, et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994; 271:1328–1334.MEDLINE
  • 34
    Werzberger A, Mensch B, Kuter B, Brown L, Lewis J, Sitrin R, Miller W, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1992; 327:453–457.MEDLINE
  • 35
    Wiens B, Bohidar N, Pigeon J, Egan J, Hurni W, Brown L, Kuter BJ, et al. Duration of protection from clinical hepatitis A disease after vaccination with VAQTA. J Med Virol 1996; 49:235–241.MEDLINE
    Direct Link:
  • 36
    Van Damme P, Thoelen S, Cramm M, De Groote K, Safary A, Meheus A. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. J Med Virol 1994; 44:446–451.MEDLINE
    Direct Link:
  • 37
    Orenstein WA, Hinman AR, Rodewald LE. Public health considerations—United States. In: SAPlotkin, WAOrenstein eds. Vaccines. Philadelphia, PA: WB Saunders Company. 1999;1006–1032.
Get PDF (83K)